Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779925 | 0.91 | KDM4E (0.41) | ALDH1A1TSHRTP53CYP3A4HSD17B10 | |
| SCHEMBL237267 | 0.82 | ALDH1A1 (0.36) | ALDH1A1TSHRTP53CYP3A4EPHX1 | |
| SCHEMBL28942386 | 0.81 | HSD17B10 (0.44) | ALDH1A1TP53CYP3A4EPHX1HSD17B10 | |
| SCHEMBL776017 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TSHRHSD17B10TDP1HTT | |
| SCHEMBL1480017 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53CYP3A4EPHX1 | |
| SCHEMBL12517329 | 0.78 | CES2 (0.46) | ALDH1A1TSHRTDP1HTTSMN1; SMN2 | |
| SCHEMBL776393 | 0.78 | CES2 (0.46) | ALDH1A1TSHRTDP1HTTSMN1; SMN2 | |
| SCHEMBL28071118 | 0.78 | CHRM2 (0.44) | TP53CYP3A4SLC6A2SLC6A4SMN1; SMN2 | |
| SCHEMBL28840080 | 0.77 | TP53 (0.42) | ALDH1A1TP53CYP3A4EPHX1SLC6A2 | |
| SCHEMBL17033364 | 0.76 | CES2 (0.44) | ALDH1A1TSHRTDP1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112741816-A | Novel colon drug delivery system | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | claimed |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR HOLDINGS, INC. (US) | 2020-08-13 | — | — | US | claimed |
| EP-3672610-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | claimed |
| CN-111225678-A | Plant and synthetic cannabinoid formulations with rapid onset and prolonged action | 受体控股公司 | 2020-06-02 | — | — | CN | claimed |
| EP-3607938-A2 | PHARMACEUTICAL COMPOSITION | Sovic Brkicic Ljiljana (HR) | 2020-02-12 | — | — | EP | claimed |
| EP-2694038-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2019-05-29 | — | — | EP | claimed |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-05-16 | — | — | US | claimed |
| US-20190125683-A1 | Once Daily Formulations Of Tetracyclines | SHIRE LABORATORIES, INC. | 2019-05-02 | — | — | US | claimed |
| WO-2019071213-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | claimed |
| US-9744137-B2 | Topiramate compositions and methods of enhancing its bioavailability | SUPERNUS PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | claimed |
| EP-0409930-A1 | PROCESS FOR FORMING ANTI-HALATION LAYERS ON POLYESTER PHOTOGRAPHIC FILM SUPPORTS. | EASTMAN KODAK CO (US) | 1991-01-30 | — | — | EP | claimed |
| WO-1990005939-A1 | PROCESS FOR FORMING ANTI-HALATION LAYERS ON POLYESTER PHOTOGRAPHIC FILM SUPPORTS | EASTMAN KODAK COMPANY (US) | 1990-05-31 | — | — | WO | claimed |
| US-4914011-A | POLYETHYLENE TEREPHTHALATE, CARBON BLACK AND CELLULOSE ACETATE HEXA HYDROPHTHALATE | EASTMAN KODAK COMPANY (US) | 1990-04-03 | — | — | US | claimed |
| US-4863744-A | Intestine drug delivery | ALZA CORPORATION (US) | 1989-09-05 | — | — | US | claimed |
| US-4705515-A | Dosage form for administering drug of the colon | ALZA CORPORATION (US) | 1987-11-10 | — | — | US | claimed |
| US-4503030-A | Device for delivering drug to certain pH environments | ALZA CORPORATION (US) | 1985-03-05 | — | — | US | claimed |
| EP-0069259-B1 | PROLONGED-ACTION FORM OF BROMOHEXINE, AND PROCESS FOR ITS PREPARATION | Dr. Karl Thomae GmbH (DE) | 1985-01-09 | — | — | EP | claimed |
| US-4438091-A | FOR RESPIRATORY DISORDERS | DR. KARL THOMAE GMBH (DE) | 1984-03-20 | — | — | US | claimed |
| US-4367217-A | Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof | BOEHRINGER INGELHEIM GMBH (DE) | 1983-01-04 | — | — | US | claimed |
| US-3957523-A | CELLULOSE DERIVATIVES | SHINETSU CHEMICAL COMPANY (JA) | 1976-05-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | ALDH1A1 1636/4885TSHR 1028/4885TP53 3506/4885 |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | FAAH, CNR1, GPR18 | ALDH1A1 4335/4885TSHR 2545/4885TP53 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.